Latest Breaking News On - Nicholash vetter - Page 1 : comparemela.com

Share this article MUNICH, Dec. 18, 2020 /PRNewswire/   Garching - OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanoma Skin Cancers (NMSCs), announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medical device. This advanced radionuclide therapy technology offers a non-invasive, single session, painless treatment with little to no scarring for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs). The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the

Shannond brownOncobeta gmbNicholash vetterAustralian institute of healthAustraliaa medical device companyOncobeta therapeutics pty ltdOncobeta therapeutics ptyMedical device companyNon melanoma skin cancersAustralian registerTherapeutic goodsBasal cellSquamous cell carcinomasAustralian instituteNon melanoma skinManaging director